Literature DB >> 28425496

3,4-Methylenedioxymethamphetamine Increases Affiliative Behaviors in Squirrel Monkeys in a Serotonin 2A Receptor-Dependent Manner.

Elizabeth G Pitts1, Adelaide R Minerva1, Erika B Chandler1, Jordan N Kohn1, Meghan T Logun1, Agnieszka Sulima2, Kenner C Rice2, Leonard L Howell1,3.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) increases sociality in humans and animals. Release of serotonin (5-HT) is thought to have an important role in the increase in social behaviors, but the mechanisms underlying these effects are poorly understood. Despite the advantages of nonhuman primate models, no studies have examined the mechanisms of the social effects of MDMA in nonhuman primates. The behavior and vocalizations of four group-housed squirrel monkeys were examined following administration of MDMA, its enantiomers, and methamphetamine. 5-HT receptor antagonists and agonists were given as drug pretreatments. Data were analyzed using linear mixed-effects models. MDMA and its enantiomers increased affiliative social behaviors and vocalizations, whereas methamphetamine had only modest effects on affiliative behaviors. Pretreatment with a 5-HT2A receptor antagonist and a 5-HT2C receptor agonist attenuated the MDMA-induced increase in social behaviors, while a 5-HT1A receptor antagonist did not alter affiliative vocalizations and increased MDMA-induced social contact. Nonhuman primates show MDMA-specific increases in affiliative social behaviors following MDMA administration, in concordance with human and rodent studies. MDMA-induced increases in social behaviors are 5-HT2A, but not 5-HT1A, receptor dependent. Understanding the neurochemical mechanisms mediating the prosocial effects of MDMA could help in the development of novel therapeutics with the unique social effects of MDMA but fewer of its limitations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28425496      PMCID: PMC5561347          DOI: 10.1038/npp.2017.80

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  41 in total

1.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

2.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

3.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

4.  A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").

Authors:  M R Thompson; P D Callaghan; G E Hunt; J L Cornish; I S McGregor
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

5.  The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys.

Authors:  J A Harder; R M Ridley
Journal:  Neuropharmacology       Date:  2000-02-14       Impact factor: 5.250

Review 6.  Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder.

Authors:  Leonard L Howell; Kathryn A Cunningham
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

7.  Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Authors:  Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

Review 8.  Functional anatomy of 5-HT2A receptors in the amygdala and hippocampal complex: relevance to memory functions.

Authors:  Cristiano Bombardi; Giuseppe Di Giovanni
Journal:  Exp Brain Res       Date:  2013-04-17       Impact factor: 1.972

9.  Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility.

Authors:  Lucia Frau; Nicola Simola; Antonio Plumitallo; Micaela Morelli
Journal:  J Neurochem       Date:  2012-11-15       Impact factor: 5.372

10.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

View more
  11 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

2.  Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.

Authors:  Daniel W Curry; Matthew B Young; Andrew N Tran; Georges E Daoud; Leonard L Howell
Journal:  Neuropharmacology       Date:  2017-10-06       Impact factor: 5.250

3.  Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

Authors:  Danilo De Gregorio; Argel Aguilar-Valles; Katrin H Preller; Boris Dov Heifets; Meghan Hibicke; Jennifer Mitchell; Gabriella Gobbi
Journal:  J Neurosci       Date:  2020-11-30       Impact factor: 6.167

4.  Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Authors:  Carine Bécamel; Dimitri De Bundel; Błażej D Pędzich; Sarah Rubens; Mehdi Sekssaoui; Anouk Pierre; Andries Van Schuerbeek; Philippe Marin; Joel Bockaert; Emmanuel Valjent
Journal:  Neuropsychopharmacology       Date:  2022-04-21       Impact factor: 8.294

Review 5.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

6.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Authors:  Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

Review 7.  Serotonin and brain function: a tale of two receptors.

Authors:  R L Carhart-Harris; D J Nutt
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

8.  Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter-mediated nonquantal dopamine release.

Authors:  Viktor Román; Rita Kedves; Kristóf Kelemen; Zsolt Némethy; Beáta Sperlágh; Balázs Lendvai; E Sylvester Vizi
Journal:  Physiol Rep       Date:  2021-11

9.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 10.  Pivotal mental states.

Authors:  Ari Brouwer; Robin Lester Carhart-Harris
Journal:  J Psychopharmacol       Date:  2020-11-11       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.